Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 10, 1996, Pages 3740-3745

  Wohllk, Nelson ^a,c   Cote, Gilbert J ^a   Bugalho, Maria M J ^a,d   Ordonez, Nelson ^a   Evans, Douglas B ^a   Goepfert, Helmuth ^a   Khorana, Sangeeta ^a   Schultz, Pamela ^a   Richards, C Sue ^b   Gagel, Robert F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Departamento de Medicina   (Chile)

^d INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CODON; DNA DETERMINATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE ENDOCRINE NEOPLASIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID CARCINOMA;

BASE SEQUENCE; CARCINOMA, MEDULLARY; CODON; DNA PRIMERS; DNA, NEOPLASM; DROSOPHILA PROTEINS; EXONS; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PEDIGREE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 10244245097     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.10.3740     Document Type: Article

References (30)

1. Eng C, Smith DP, Mulligan LM, et al. 1995 A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene. 10:509-513.
2. Mulligan LM, Kwok JBJ, Healey CS, et al. 1993 Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (MEN 2A). Nature. 363:458-460.
3. Donis-Keller H, Dou S, Chi D, et al. 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 2:851-856.
4. Hofstra RMW, Landsvater RM, Ceccherini I, et al. 1994 A mutation in the RET proto-onocogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 367:376-376.
5. Donis-Keller H, Shenshen D, Chi D, et al. 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 2:851-856.
6. Carlson KM, Dou S,Chi D, et al. 1994 Singlemissensemutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA. 91:1579-1583.
7. Carlson KM, Bracamontes J, Jackson CE, et al. 1994 Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet. 55:1076-1082.
8. van Heyningen V. 1994 One gene-four syndromes. Nature. 367:319-320.
9. Eng C, Smith D, Mulligan L, et al. 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 3:237-241.
10. Eng C, Mulligan L, Smith D, et al. 1995 Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes, Chromosomes & Cancer. 12:209-212.
11. Blaugrund JE, Johns MM, Jr, Eby YJ, et al. 1994 RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet. 3:1895-1897.
12. Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C. 1994 Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum Mol Genet. 3:1259-1262.
13. Eng C, Smith DP, Mulligan LM, et al. 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 3:237-241.
14. Asai N, Iwashita T, Matsuyama M, Takahashi M. 1995 Mechansims of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol. 15:1613-1619.
15. Santoro M, Carlomagno F, Romano A, et al. 1995 Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science. 267:381-383.
16. Wells SA, Chi DD, Toshima K, et al. 1994 Predictive DNA testing and prophylactic thyrodectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg. 220:237-250.
17. Lips CJM, Landsvater RM, Höppener JWM, et al. 1994 Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med. 331:828-835.
18. Gagel RF, Cote GC. 1994 Decision making in multiple endocrine neoplasia type 2. In: Mazzaferri EL, Bar RS, Kreisberg RA, eds. Advances in endocrinology and metabolism. Vol. 5. St. Louis, MO; Mosby: pp 1-23.
19. Gagel RF, Cote GJ, Martins Bugalho MJG, et al. 1995 Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. J Int Med. 238:333-341.
20. Donovan DT, Gagel RF. 1990 Medullary thyroid carcinoma and the multiple endocrine neoplasia syndromes. In: Falk SA, ed. Thyroid disease: endocrinology, surgery, nuclear medicine, and radiotherapy. 1st ed. New York; Raven Press: pp 501-525.
21. Khorana S, Gagel RF, Cote GJ. 1994 Direct sequencing of PCR products in agarose gel slices. Nucleic Acids Res. 22:3425-3426.
22. Wright DK, Manos MM. 1990 Sample preparation from paraffin-embedded tissues. In: Sninsky JJ, White TJ, eds. PCR protocols: a guide to methods and applications. New York; Academic Press: pp 153-158.
23. Bannerjee SK, Makdisi WF, Weston AP, Mitchell SM, Campbell DR. 1995 Microwave-based DNA extraction from paraffin-embedded tissue for PCR amplification. Biotechniques. 18:768-773.
24. Bugalho MJ, Cote GJ, Khorana S, Schultz PN, Gagel RF. 1994 Identification of a polymorphism in exon 11 of the RET protooncogene. Hum Mol Genet. 3:2263.
25. Alford RL, Hammond HA, Coto I, Caskey CT. 1994 Rapid and efficient resolution of parentage by amplification of short tandem repeats. Am J Hum Genet. 55:190-195.
26. Hammond HA, Jin L, Zhong Y, Caskey CT, Chakraborty R. 1994 Evaluation of 13 short andem repeat loci for use in personal identification applications. Am J Hum Genet. 55:175-189.
27. Gardner E, Mulligan LM, Eng C, et al. 1994 Haplotype analysis of MEN 2 mutations. Hum Mol Genet. 3:1771-1774.
28. Mulligan LM, Eng C, Healey CS, et al. 1994 A de novo mutation of the ret proto-oncogene in a patient with MEN 2A. Hum Mol Genet. 3:1007-1008.
29. Decker RA, Peacock ML, Borst MJ, Sweet JD, Thompson NW. 1995 Progress in genetic screening of multiple endocrine neoplasia type 2A: Is calcitonin testing obsolete? Surgery. 118:257-264.
30. Komminoth P, Kunz EK, Matias-Guiu X, et al. 1995 Analysis of RET proto-oncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer. 76:479-489.